To determine whether vimentin, survivin, and cyclin D1 function as downstream effectors of the JAK2/STAT3 pathway in ESCC, we performed plasmid-based overexpression of each gene in fedratinib-treated cells. The gene discussed is BIRC5; the disease is esophageal squamous cell carcinoma.